{"id":"NCT00157157","sponsor":"Baxalta now part of Shire","briefTitle":"Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients","officialTitle":"Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-04-01","primaryCompletion":"2009-09-11","completion":"2009-09-11","firstPosted":"2005-09-12","resultsPosted":"2011-07-15","lastUpdate":"2021-05-24"},"enrollment":66,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)","otherNames":[]}],"arms":[{"label":"Single Arm - All Participants","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII (FVIII) before.","primaryOutcome":{"measure":"Factor VIII Inhibitor Development","timeFrame":"Assessed during study period which was to be at least 75 exposure days or 3 years (whichever came first)","effectByArm":[{"arm":"PUPs","deltaMin":29.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":35,"countries":["United States","Austria","Canada","France","Germany","Italy","Puerto Rico","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["19216617","22476554"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":55},"commonTop":["Pyrexia","Nasopharyngitis","Cough","Rhinorrhoea","Diarrhea"]}}